Clinical Trial

Everolimus Aging Study

Study acronym: EVERLAST
Completed Phase 2
View on ClinicalTrials.gov →
Summary
The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5 mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular hallmarks of aging in humans. Participants who are 55-80 years old and insulin resistant or prediabetic will be randomized to treatment and can expect to be on study for up to approximately 38 weeks. Participants aged 18-35 will not receive the intervention and can expect to be on study for up to approximately 8 weeks.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-11
notable Primary completion moved earlier: 2026-09 -> 2026-06-30 2026-08-11
minor Completion moved earlier: 2026-09 -> 2026-07-22 2026-08-11
Trial Details
NCT Number NCT05835999
Lead Sponsor University of Wisconsin, Madison
Collaborators: National Institute on Aging (NIA)
Conditions Aging, Insulin Resistance
Enrollment 106 participants
Start Date 2023-03-24
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-07-22 (estimated)
Updated on ClinicalTrials.gov 2026-08-10